← All trials
NCT02754583
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- Jan 1, 2019
- Completion date
- Jul 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 220000
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- University of California, San FranciscoStudy director
- Emory UniversityCollaborator
- National Eye Institute (NEI)Collaborator
- The Carter CenterCollaborator
- Bahir Dar Regional Health and Research LaboratoryCollaborator
- The Carter CenterStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.